摘要
伴随着组蛋白去乙酰化酶抑制剂(histone deacetylase inhibitor,HDACi)这一类靶向表观遗传调控机制的药物的创新发展,乳腺癌患者的治疗格局正在被逐渐改变。无论是激素受体(hormone receptor,HR)阳性且人表皮生长因子受体2(hu⁃man epidermal growth factor receptor 2,HER2)阴性乳腺癌患者还是三阴性乳腺癌(triple⁃negative breast cancer,TNBC)患者,都能够从HDACi联合治疗方案中取得可观的临床获益。文章围绕HDACi这一类药物,总结其在乳腺癌各个分子亚型中应用的研究进展,特别是总结了中国人群的治疗现状,对未来联合用药方案合理布局的探索进行综述。
With the innovative development of histone deacetylase inhibitors(HDACi),a class of drugs targeting epigenetic regulation mechanism,the treatment landscape for breast cancer patients is gradually changing.Both hormone receptor⁃positive and human epidermal growth factor receptor 2⁃negative breast cancer patients,as well as triple⁃negative breast cancer(TNBC)patients,can benefit significantly from combination therapy with HDACi.This article summarizes the research progress of HDACi in various molecular subtypes of breast cancer,with a particular focus on the treatment status in the Chinese population and exploration of rational combination therapy strategies in the future.
作者
刘谦
瞿菲
李薇
LIU Qian;QU Fei;LI Wei(Department of Oncology,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China)
出处
《南京医科大学学报（自然科学版）》
CAS
北大核心
2024年第2期281-286,共6页
Journal of Nanjing Medical University(Natural Sciences)
基金
国家自然科学基金面上项目(81772475)
江苏省自然科学基金面上项目(BK20191355)。
